CA3131596A1 - Novel iron compositions and methods of making and using the same - Google Patents

Novel iron compositions and methods of making and using the same Download PDF

Info

Publication number
CA3131596A1
CA3131596A1 CA3131596A CA3131596A CA3131596A1 CA 3131596 A1 CA3131596 A1 CA 3131596A1 CA 3131596 A CA3131596 A CA 3131596A CA 3131596 A CA3131596 A CA 3131596A CA 3131596 A1 CA3131596 A1 CA 3131596A1
Authority
CA
Canada
Prior art keywords
iron
composition
sucrose
aqueous
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3131596A
Other languages
English (en)
French (fr)
Inventor
Donald Jeffrey Keyser
Alvaro F. Guillem
Richard A. ZAGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Renibus Therapeutics Inc
Original Assignee
Renibus Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renibus Therapeutics Inc filed Critical Renibus Therapeutics Inc
Publication of CA3131596A1 publication Critical patent/CA3131596A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA3131596A 2019-02-28 2020-02-28 Novel iron compositions and methods of making and using the same Pending CA3131596A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962812028P 2019-02-28 2019-02-28
US62/812,028 2019-02-28
PCT/US2020/020517 WO2020176894A1 (en) 2019-02-28 2020-02-28 Novel iron compositions and methods of making and using the same

Publications (1)

Publication Number Publication Date
CA3131596A1 true CA3131596A1 (en) 2020-09-03

Family

ID=70190086

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3131596A Pending CA3131596A1 (en) 2019-02-28 2020-02-28 Novel iron compositions and methods of making and using the same

Country Status (20)

Country Link
US (4) US11292813B2 (https=)
EP (2) EP3930686B1 (https=)
JP (3) JP7320611B2 (https=)
KR (1) KR20210133243A (https=)
CN (2) CN119488480A (https=)
AU (2) AU2020229381A1 (https=)
CA (1) CA3131596A1 (https=)
DK (1) DK3930686T3 (https=)
ES (1) ES2955019T3 (https=)
FI (1) FI3930686T3 (https=)
HR (1) HRP20230989T1 (https=)
HU (1) HUE063182T2 (https=)
LT (1) LT3930686T (https=)
PL (1) PL3930686T3 (https=)
PT (1) PT3930686T (https=)
RS (1) RS64652B1 (https=)
SG (1) SG11202109323UA (https=)
SI (1) SI3930686T1 (https=)
SM (1) SMT202300276T1 (https=)
WO (1) WO2020176894A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022056378A1 (en) * 2020-09-11 2022-03-17 Renibus Therapeutics, Inc. Method for treating cancer with kidney protection
WO2024069644A1 (en) * 2022-09-30 2024-04-04 West Bengal Chemical Industries Limited A pharmaceutically acceptable ferric carboxymaltose and preparation thereof
CN115969714B (zh) * 2022-11-03 2025-03-11 华熙生物科技股份有限公司 具有光谱选择性的防晒组合物及其应用
WO2025047574A1 (ja) 2023-08-29 2025-03-06 株式会社ダイセル 硬化性エポキシ組成物

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE862482C (de) * 1950-05-14 1953-01-12 Merck Chem Fab E Verfahren zur Darstellung haltbarer, injizierbarer Loesungen von Salzen des dreiwertigen Eisens
US5624668A (en) 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations
DE19547356A1 (de) * 1995-12-19 1997-06-26 Vifor Int Ag Adsorbens für Phosphat aus wäßrigem Medium, dessen Herstellung und Verwendung
US20030232738A1 (en) * 1998-04-20 2003-12-18 National Jewish Medical And Research Center Method and composition for increasing CD4+ T lymphocyte immune responsiveness
CA2365787C (en) * 2000-12-20 2006-02-14 Dialysis Solutions Inc. Sterile low bicarbonate dialysis concentrate solutions
WO2004019032A1 (en) * 2002-08-26 2004-03-04 Luitpold Pharmaceuticals, Inc. Bioequivalence test for iron-containing formulations
WO2005094202A2 (en) * 2004-03-16 2005-10-13 Navinta, Llc Iron sucrose complexes and method of manufacture thereof
EP1819720B1 (en) 2004-12-06 2013-05-15 Emcure Pharmaceuticals Limited A cost-effective process for preparation of manufacture of iron sucrose
ITMO20050056A1 (it) 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
CN100528237C (zh) 2005-04-26 2009-08-19 重庆医药工业研究院有限责任公司 多核的氢氧化铁-糖复合物的制备方法
EP1757299A1 (de) * 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
US7960371B2 (en) 2006-10-04 2011-06-14 Infacare Pharmaceutical Corporation High-purity large-scale preparation of stannsoporfin
EP1947120A1 (de) 2007-01-19 2008-07-23 Vifor (International) Ag Eisen-Kohlenhydrat-Komplex-Verbindungen
IN269965B (https=) 2007-06-25 2015-11-27 Claris Lifescienses Ltd
TWI592159B (zh) 2007-11-16 2017-07-21 威佛（國際）股份有限公司 藥學組成物
AR076070A1 (es) * 2009-03-02 2011-05-18 Vifor Int Ag Absorbente de fosfato para el tratamiento de la hiperfosfatemia
CN102451185A (zh) * 2010-10-19 2012-05-16 长春纳米生技公司 金属离子纳米簇组合物
EP2548562A1 (de) 2011-07-18 2013-01-23 SeBo GmbH Kombinationstherapie mit Eisen-basierenden Phosphatadsorbern
EP2647389A1 (en) * 2012-04-04 2013-10-09 Charité - Universitätsmedizin Berlin Magnetic nanoparticle dispersion, its preparation and diagnostic and therapeutic use
CN103340827B (zh) 2013-07-16 2014-12-10 成都天台山制药有限公司 蔗糖铁注射液及其制法
CN104558064A (zh) 2013-10-29 2015-04-29 北京京卫信康医药科技发展有限公司 蔗糖铁的制备方法
IN2013CH05383A (https=) 2013-11-21 2015-08-28 Reddy’S Lab Ltd Dr
CN104098616B (zh) 2014-05-27 2016-04-20 广西壮族自治区化工研究院 一种蔗糖铁的制备方法
SI3200582T1 (sl) * 2014-09-29 2024-04-30 Fred Hutchinson Cancer Center Sestave, kompleti in metode za indukcijo pridobljene citorezistence z uporabo induktorjev stresnih proteinov
WO2017165692A1 (en) * 2016-03-23 2017-09-28 Fred Hutchinson Cancer Research Center Compounds linked with a saccharide metal complex and uses thereof
US20190358242A1 (en) * 2017-02-08 2019-11-28 Fred Hutchinson Cancer Research Center Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
HUE070809T2 (hu) 2017-09-11 2025-07-28 Pharmacosmos Holding As Vaskomplex vegyületek gyógyászati alkalmazásra
CN109912675B (zh) 2017-12-13 2020-09-15 北京市林业果树科学研究院 一种蔗糖亚铁及其制备方法
CN110063965A (zh) 2019-06-04 2019-07-30 吉林省富生医疗器械有限公司 一种血液透析浓缩物
CN112315902B (zh) 2019-08-05 2022-05-13 南京恒生制药有限公司 一种低易变铁含量蔗糖铁注射液制备方法
CN112168844A (zh) 2020-09-29 2021-01-05 神奈纳米医药技术(珠海)有限公司 一种氢氧化铁碳水化合物复合物的制备方法
MY210100A (en) 2020-09-29 2025-08-27 Lg Bionano Llc Methods of preparing iron complexes
CN112156109A (zh) 2020-09-29 2021-01-01 神奈纳米医药技术(珠海)有限公司 氢氧化铁-糖络合物的制备方法及其应用
CN115531414A (zh) 2021-06-30 2022-12-30 南京恒生制药有限公司 一种新型蔗糖铁复合物及其制备方法
CN118103047A (zh) 2021-08-27 2024-05-28 美国瑞根特有限公司 铁组合物及其制备和使用方法

Also Published As

Publication number Publication date
ES2955019T3 (es) 2023-11-28
US11292813B2 (en) 2022-04-05
US11840552B2 (en) 2023-12-12
KR20210133243A (ko) 2021-11-05
US11834471B2 (en) 2023-12-05
SMT202300276T1 (it) 2023-11-13
SG11202109323UA (en) 2021-09-29
CN113825496B (zh) 2024-09-27
FI3930686T3 (fi) 2023-09-01
WO2020176894A1 (en) 2020-09-03
HRP20230989T1 (hr) 2023-12-08
HUE063182T2 (hu) 2024-01-28
PL3930686T3 (pl) 2023-11-27
JP2022522009A (ja) 2022-04-13
JP7646750B2 (ja) 2025-03-17
CN113825496A (zh) 2021-12-21
AU2020229381A1 (en) 2021-09-16
EP3930686A1 (en) 2022-01-05
JP2023139154A (ja) 2023-10-03
US20230070012A1 (en) 2023-03-09
CN119488480A (zh) 2025-02-21
LT3930686T (lt) 2023-10-10
DK3930686T3 (da) 2023-09-11
RS64652B1 (sr) 2023-10-31
EP4234020A3 (en) 2023-10-04
PT3930686T (pt) 2023-09-04
JP7320611B2 (ja) 2023-08-03
US20220242901A1 (en) 2022-08-04
US20200277325A1 (en) 2020-09-03
US20240002427A1 (en) 2024-01-04
JP2025084949A (ja) 2025-06-03
AU2025230678A1 (en) 2025-10-02
EP4234020A2 (en) 2023-08-30
SI3930686T1 (sl) 2023-11-30
EP3930686B1 (en) 2023-05-31

Similar Documents

Publication Publication Date Title
US11834471B2 (en) Iron compositions and methods of making and using the same
Himmelstoß et al. Long‐term colloidal and chemical stability in aqueous media of NaYF4‐type upconversion nanoparticles modified by ligand‐exchange
Jahn et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implications
Mignot et al. A Top‐Down synthesis route to ultrasmall multifunctional Gd‐Based silica nanoparticles for theranostic applications
Alanazi et al. Selective and reliable fluorometric quantitation of anti-cancer drug in real plasma samples using nitrogen-doped carbon dots after MMIPs solid phase microextraction: Monitoring methotrexate plasma level
Subedi et al. Highly efficient fluorescent probes from chitosan-based amino-functional carbon dots for the selective detection of Cu2+ traces
Poodat et al. A new nano-delivery system for cisplatin using green-synthesized iron oxide nanoparticles
Xiao et al. Uncovering the role of free lanthanum (La3+) ions and La oligomer on the surface of La (oxy) hydroxide particles for phosphate removal
HK40098133A (en) Novel iron compositions and methods of making and using the same
HK40066891B (en) Novel iron compositions and methods of making and using the same
HK40066891A (en) Novel iron compositions and methods of making and using the same
Barui et al. Dual drug loaded nanotheranostic platforms as a novel synergistic approach to improve pancreatic cancer treatment
HK40066204A (zh) 新型铁组合物及其制造和使用方法
HK40066204B (zh) 新型铁组合物及其制造和使用方法
Chang et al. Carbon-13 Fourier transform nuclear magnetic resonance study of gallium citrate in aqueous solution
Cardoso et al. Radiation-induced copper oxide formation in a clinical gel composite: a novel approach for dosimetry
Ortiz-Vergara et al. Interactions between magnetic and luminescent phases in hybrid nanomaterials composed of magnetite nanoparticles assembled within a cross-conjugated polymer
Marcinkowska et al. Cisplatin Derivatives and Their Complexes with PAMAM Dendrimers—A Way to Improve the Efficacy of Anticancer Drugs
Jeżowska‐Bojczuk et al. Identification of copper (II) binding sites in the aminoglycosidic antibiotic neomycin B
Zhang et al. Self-assembly of a surfactant-encapsulated polyoxometalate mediated by coordination of metal ions
Mangione et al. Short-Chain Alkanethiol Coating for Small-Size Gold Nanoparticles Supporting Protein Stability
Mejias Characterization of titanium (IV)-transferrin binding interactions
Cardona Mejías Characterization of Ti (IV)-transferring binding interactions
Kulakov et al. Structural study of bismuth complexes with diethylenetriaminepentaacetic acid in aqueous solutions
Singer An Electron Spin Resonance Study of the Photoreduction of Potassium Octacyanomolybdate V

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220908

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250221

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250602

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250602

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250602

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250819

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250903

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20251001

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251001

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251002

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20251002

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251002

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251002

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251002

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251002

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251028